Ramiah Investment Group has filed a Form 13F-HR with the Securities and Exchange Commission, disclosing its equity portfolio as of the close of business on September 30, 2026. The filing, submitted by CEO Daena Ramiah, lists a total of 76 individual holdings.
The portfolio is heavily weighted toward exchange-traded funds (ETFs), with 49 of the 76 entries being ETFs. Among the individual equities, AbbVie Inc. is the largest holding, with 1,784 shares. Other notable individual stock positions include Amgen Inc. (1,402 shares), CrowdStrike Holdings Inc. Class A (1,024 shares), and Merck & Co. Inc. (4,094 shares).
The filing also lists significant positions in various Vanguard ETFs, including the Vanguard Total Stock Market ETF (37,396 shares) and the Vanguard S&P 500 ETF (27,430 shares). Additionally, the portfolio includes positions in the iShares MSCI Emerging Markets ETF (33,428 shares) and the iShares Core S&P Small-Cap ETF (18,160 shares).
